Responses
Section 4: Clinical pharmacy services
4CPS-219 Agamenon-seom model for the prediction of survival in patients with HER2-positive advanced oesophagogastric adenocarcinoma receiving trastuzumab-based first-line treatment
Compose a Response to This Article
Other responses
No responses have been published for this article.